BPTH News Alert Bio-Path Holdings (BPTH) 2.23 02/14/2015 19:

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 8:55 PM

Bio-Path Holdings (BPTH) 2.23 $BPTH

Bio-Path Holdings moves Liposomal Grb-2 into the next phase of clinical development in AML patients
M2 - Tue Feb 10, 5:10AM CST
Biotechnology company Bio-Path Holdings (NasdaqCM:BPTH) reported on Monday that it has started enrollment under the safety segment of its Phase 2 study evaluating BP-100-1.01 (Liposomal Grb-2) in acute myeloid leukemia (AML) patients.
BPTH: 2.23 (-0.02)

Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients
Business Wire - Mon Feb 09, 7:30AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrollment into the safety segment of its Phase 2 study evaluating BP-100-1.01 (Liposomal Grb-2) in patients with acute myeloid leukemia (AML).
BPTH: 2.23 (-0.02)

Bio-Path Holdings' Liposomal Grb-2 Featured in Peer-Reviewed Journal "Expert Opinion on Drug Delivery"
Business Wire - Wed Jan 07, 7:00AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that data from pre-clinical studies of BP-100-1.01 (Liposomal Grb-2) were featured in the peer-reviewed journal Expert Opinion on Drug Delivery.
BPTH: 2.23 (-0.02)

Bio-Path Holdings to Present at the Biotech Showcase(TM) 2015 Conference
Business Wire - Tue Jan 06, 9:00AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase(TM) 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time.
BPTH: 2.23 (-0.02)

Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma
Business Wire - Mon Dec 22, 7:30AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma. Bio-Path has a completed preclinical package of toxicity, tissue distribution, pharmacokinetics and efficacy studies. The Company plans to file an Investigational New Drug application (IND) in the first half of 2015.
BPTH: 2.23 (-0.02)

Thyroid and Esophageal Cancer Therapeutic Pipeline Market (Drugs & Companies) Review H2 2014
PRWeb - Sat Dec 06, 11:30PM CST
The report "Thyroid Cancer Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/thyroid-canc...eport.html .
BPTH: 2.23 (-0.02), VBLT: 14.11 (+0.24), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 11:46AM CST

NETE: 1.29 (+0.14), ANV: 0.97 (-0.03), LXRX: 0.89 (unch), CYAN: 8.72 (+0.13), JMEI: 12.67 (+0.31), LQDT: 9.52 (+0.09), KIRK: 25.87 (-0.30), IMNP: 1.87 (-0.03), RMTI: 11.17 (+0.15), FES: 1.19 (+0.06), DWCH: 6.26 (-0.18), AMDA: 0.65 (+0.01), CYBX: 57.03 (+0.26), BAMM: 2.57 (+0.01), CRMT: 51.79 (-0.25), EDAP: 3.55 (+0.13), BPTH: 2.23 (-0.02), MAGS: 4.91 (+0.15), RITT: 1.29 (unch), ENG: 1.85 (-0.06)

Bio-Path Q3 results
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:36AM CST

BPTH: 2.23 (-0.02)

Bio-Path posts 3Q loss
Automated Insights - Mon Nov 17, 7:43AM CST
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $1.1 million, or 1 cent per share, in its third quarter.
BPTH: 2.23 (-0.02)

Bio-Path EPS in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:39AM CST

BPTH: 2.23 (-0.02)

Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results
Business Wire - Mon Nov 17, 7:30AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the third quarter ended September 30, 2014.
BPTH: 2.23 (-0.02)

Bio-Path Holdings appoints Dr Amy P. Sing to its board
M2 - Fri Nov 07, 6:22AM CST
Biotechnology company Bio-Path Holdings (NasdaqCM:BPTH) revealed on Thursday the addition of Dr Amy P. Sing, MD to its board of directors, bringing the number of board members to five.
BPTH: 2.23 (-0.02)

Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors
Business Wire - Thu Nov 06, 9:35AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Amy P. Sing, M.D. to its Board of Directors, bringing the number of board members to five.
BPTH: 2.23 (-0.02)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), STML: 14.07 (-0.10), SNTA: 2.29 (-0.03), KBIO: 0.45 (+0.06), BPTH: 2.23 (-0.02), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)

OTC Daily Alert Stock Watch - Bio-Path Holdings, Inc., (NASDAQ: BPTH)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
BPTH: 2.23 (-0.02)

Bio-Path Holdings, Inc. (Nasdaq: BPTH) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Oct 16, 9:33AM CDT
--
BPTH: 2.23 (-0.02), NDAQ: 49.48 (-0.27)

Bio-Path Holdings successfully concludes Cohort six of Phase I clinical trial of Liposomal Grb-2 in blood cancer patients
M2 - Wed Oct 08, 6:24AM CDT
Biotechnology company Bio-Path Holdings (NasdaqCM :BPTH) disclosed on Tuesday the successful completion of Cohort 6 under its Phase I blood cancer clinical trial of its lead compound, Liposomal Grb-2.
BPTH: 2.23 (-0.02)

Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers
Business Wire - Tue Oct 07, 7:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has successfully completed Cohort 6 of its Phase I clinical trial evaluating lead compound, Liposomal Grb-2, in blood cancers. Bio-Path now plans to move the compound into Phase II clinical trials.
BPTH: 2.23 (-0.02)

Bio-Path Holdings to Present at the 13th Annual BIO Investor Forum
Business Wire - Tue Sep 30, 9:00AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the 13th Annual BIO Investor Forum Conference in San Francisco on Tuesday, October 7, 2014 at 10:00 a.m. Pacific Time (1:00pm Eastern Time).
BPTH: 2.23 (-0.02)

Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results
Business Wire - Mon Aug 18, 7:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"

, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the second quarter ended June 30, 2014.
BPTH: 2.23 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...